RecruitingNCT06885905
Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being
Sponsor
Imperial College London
Enrollment
100 participants
Start Date
Nov 27, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with chronic pulmonary aspergillosis. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06885905
Related Trials
Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
NCT054449462 locations
Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
NCT0679455437 locations
iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
NCT062449791 location
Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study
NCT056531931 location
Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole
NCT036560811 location